WO2020108154A1 - 一种雌激素受体下调剂的盐型、晶型及其制备方法 - Google Patents
一种雌激素受体下调剂的盐型、晶型及其制备方法 Download PDFInfo
- Publication number
- WO2020108154A1 WO2020108154A1 PCT/CN2019/111624 CN2019111624W WO2020108154A1 WO 2020108154 A1 WO2020108154 A1 WO 2020108154A1 CN 2019111624 W CN2019111624 W CN 2019111624W WO 2020108154 A1 WO2020108154 A1 WO 2020108154A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- ray powder
- powder diffraction
- diffraction pattern
- Prior art date
Links
- HUQVRIJCSRWPQV-CCDJVQBGSA-N CC/C(/c(c(Cl)c1)ccc1F)=C(\c([nH]c1ccccc11)c1Cl)/c1ccc(/C=C/C(O)=O)cc1 Chemical compound CC/C(/c(c(Cl)c1)ccc1F)=C(\c([nH]c1ccccc11)c1Cl)/c1ccc(/C=C/C(O)=O)cc1 HUQVRIJCSRWPQV-CCDJVQBGSA-N 0.000 description 1
- QHQZEEGNGSZBOL-UHFFFAOYSA-O [NH3+]CC(CO)(CO)CO Chemical compound [NH3+]CC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the invention relates to a salt form and a crystal form of an estrogen receptor down-regulator and a preparation method thereof, and further includes the application of the salt form and the crystal form in preparing a medicine for treating breast cancer.
- breast cancer has become the second highest incidence cancer in the world and the highest incidence among women.
- the role of the estrogen-estrogen receptor signaling pathway in the development of breast cancer has been determined; and the estrogen receptor (ER) has also developed into the most important biomarker for breast cancer.
- ER estrogen receptor
- breast cancer can be divided into estrogen receptor positive breast cancer and estrogen receptor negative breast cancer; among them, estrogen receptor positive breast cancer accounts for more than 70% of the total breast cancer patients .
- Endocrine Therapy which targets the estrogen-estrogen receptor signaling pathway in breast cancer cells, has become the first choice for the treatment of estrogen receptor-positive breast cancer because of its minimal harm and remarkable efficacy.
- Endocrine therapy mainly includes the following three treatment methods: ovarian suppression therapy, aromatase inhibitor (Aromatase inhibitor, AI), selective estrogen receptor modulator (Selective Etrogen receptor modulator, SERM). Ovarian suppression therapy is less effective than the other two therapies because of its unsatisfactory efficacy and low patient satisfaction.
- aromatase inhibitor letrozole and the selective estrogen receptor modulator tamoxifen have shown good efficacy in the treatment of estrogen receptor-positive breast cancer, with the application of two types of drugs, estrogen Receptor-positive breast cancer resistance to aromatase inhibitors and selective estrogen receptor modulators has become increasingly prominent.
- estrogen receptors can produce corresponding mutations.
- the mutated estrogen receptor can maintain its agitated conformation in the absence of estrogen, allowing it to continue to function as a receptor to promote breast cancer cell proliferation.
- the mechanism of resistance of breast cancer cells to the selective estrogen receptor modulator tamoxifen is complex and diverse.
- breast cancer cells can compensate for the lack of function of estrogen receptor activation domain-2 (AF-2) due to tamoxifen by activating the function of estrogen receptor activation domain-1 (AF-1).
- breast cancer cells can adapt to the conformation of the estrogen receptor after being combined with tamoxifen by adjusting the structure or concentration of the estrogen receptor coactivator, so that the function of the estrogen receptor is restored, thereby causing drug resistance.
- Selective estrogen receptor down-regulator has shown its unique advantages in the treatment of breast cancer resistant to the two hormone therapy.
- selective estrogen receptor down-regulators antagonize the function of estrogen receptors, which can greatly accelerate the ubiquitination degradation of estrogen receptors (normal or variant) in breast cancer cells, completely blocking estrogen/estrogen The receptor signaling pathway achieves the purpose of inhibiting the growth and proliferation of normal or drug-resistant breast cancer cells.
- selective estrogen receptor downregulators can effectively inhibit the proliferation of hormone-resistant breast cancer cells.
- Fulvestrant Fulvestrant
- fulvestrant itself has many problems. First, because of its poor PK properties, fulvestrant showed zero oral bioavailability; at the same time, fulvestrant had a higher blood clearance rate. For the above two reasons, this drug can only be administered by intramuscular injection. However, due to its strong esterophilic structure, fulvestrant administered intramuscularly also has serious problems in tissue distribution. Therefore, the development of selective estrogen receptor down-regulators with oral bioavailability is an urgent medical need.
- WO2012037411A2 reported that the oral selective estrogen receptor down-regulator ARN-810, a clinical phase II trial of this molecule in the treatment of ER-positive breast cancer is underway. According to reports [J.Med.Chem.2015,58(12),4888-4904], the important pharmacophore of the molecule is the indazole structure on the left side of the molecule. The nitrogen atom in the indazole structure acts as a hydrogen bond acceptor Estrogen receptor binding.
- WO2017162206A1 reports a series of oral selective estrogen receptor down-regulating agents, including the preparation of compound I-8 (Example 8 in WO2017162206A1) and its biological activity:
- the present invention provides compounds of formula (I),
- the present invention also provides the crystalline form A of the compound of formula (I), characterized in that its X-ray powder diffraction pattern measured using Cu-K ⁇ has characteristic diffraction peaks at the following 2 ⁇ angles: 5.52 ⁇ 0.2°, 13.68 ⁇ 0.2° , 19.98 ⁇ 0.2°, 20.80 ⁇ 0.2°, 22.02 ⁇ 0.2°, 22.44 ⁇ 0.2°, 24.94 ⁇ 0.2° and 26.96 ⁇ 0.2°,
- the above crystalline form A is characterized in that the X-ray powder diffraction pattern measured by Cu-K ⁇ is in nine or more, ten or more, or eleven or There are more characteristic diffraction peaks at the 2 ⁇ angle selected from the group: 5.52 ⁇ 0.2°, 13.68 ⁇ 0.2°, 18.86 ⁇ 0.2°, 19.98 ⁇ 0.2°, 20.80 ⁇ 0.2°, 21.62 ⁇ 0.2°, 22.02 ⁇ 0.2° , 22.44 ⁇ 0.2°, 23.34 ⁇ 0.2°, 24.94 ⁇ 0.2°, 26.96 ⁇ 0.2° and 28.42 ⁇ 0.2°.
- the above crystalline form A the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 1.
- the above Form A has a differential scanning calorimetry curve with an endothermic peak at 239.46°C ⁇ 3°C.
- the above-mentioned crystal form A has a differential scanning calorimetry curve as shown in FIG. 2.
- the present invention also provides Form B of the compound of formula (I), characterized in that its X-ray powder diffraction pattern measured using Cu-K ⁇ has characteristic diffraction peaks at the following 2 ⁇ angles: 5.68 ⁇ 0.2°, 12.36 ⁇ 0.2° , 19.24 ⁇ 0.2°, 19.86 ⁇ 0.2°, 20.62 ⁇ 0.2°, 21.64 ⁇ 0.2°, 22.68 ⁇ 0.2° and 24.96 ⁇ 0.2°.
- the above crystalline form B is characterized in that the X-ray powder diffraction pattern measured by Cu-K ⁇ is in nine or more, ten or more, or eleven or More selected characteristic diffractions at 2 ⁇ angles from the group: 5.68 ⁇ 0.2°, 12.36 ⁇ 0.2°, 13.42 ⁇ 0.2°, 19.24 ⁇ 0.2°, 19.86 ⁇ 0.2°, 20.62 ⁇ 0.2°, 21.64 ⁇ 0.2°, 22.68 ⁇ 0.2°, 24.96 ⁇ 0.2°, 26.38 ⁇ 0.2°, 27.44 ⁇ 0.2° and 30.62 ⁇ 0.2°.
- the above-mentioned crystal form B, the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 3.
- the invention also provides compounds of formula (II),
- the present invention also provides the crystalline form C of the compound of formula (II), the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 4.
- the invention also provides compounds of formula (III),
- the present invention also provides the crystalline form D of the compound of formula (III).
- the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 5.
- the present invention also provides the crystalline form E of the compound of formula (III).
- the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 6.
- the invention also provides compounds of formula (IV),
- the present invention also provides the crystalline form F of the compound of formula (IV).
- the X-ray powder diffraction pattern measured by Cu-K ⁇ is shown in FIG. 7.
- the present invention also provides the crystalline form G of the compound of formula (IV), the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 8.
- the invention also provides compounds of formula (V),
- the present invention also provides the crystalline form H of the compound of formula (V), and the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 9.
- the present invention also provides the crystalline form I of the compound of formula (V).
- the X-ray powder diffraction pattern measured by Cu-K ⁇ is shown in FIG. 10.
- the present invention also provides the crystalline form J of the compound of formula (V).
- the X-ray powder diffraction pattern measured by Cu-K ⁇ is shown in FIG. 11.
- the invention also provides compounds of formula (VI),
- the present invention also provides the crystalline form K of the compound of formula (VI), and the X-ray powder diffraction pattern measured using Cu-K ⁇ is shown in FIG. 12.
- the invention also provides the application of the above compound or crystal form in the preparation of a medicine for treating breast cancer.
- intermediate compounds of the present invention can be prepared by various synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by the combination with other chemical synthesis methods, and those skilled in the art.
- Well-known equivalent alternatives, preferred embodiments include but are not limited to the examples of the present invention.
- Pd(OAc) 2 represents palladium acetate
- Pd(PPh 3 ) 2 Cl 2 represents bis(triphenylphosphine) palladium dichloride
- Pd(PPh 3 ) 3 Cl represents rhodium tris(triphenylphosphine) chloride
- Pd(OH) 2 represents palladium hydroxide
- Xantphos represents 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene
- Xphos stands for 2-dicyclohexylphosphonium-2',4',6'-triisopropylbiphenyl
- BINAP stands for ( ⁇ )-2,2'-bis-(diphenylphosphino)-1,1'- Binaphthalene
- Xantphos represents 4,5-bis-(diphenylphosphino)-9,9-dimethylxanthene
- Xphos-Pd-G1 represents chloro(2-dicy
- Test method about 10 ⁇ 20mg sample is used for XRPD detection.
- Light tube voltage 40kV
- light tube current 40mA
- Anti-scattering slit 7.10mm.
- Step size 0.02deg.
- Step size 0.12 seconds.
- DSC Differential Scanning Calorimeter
- Test method Take a sample ( ⁇ 1mg) and place it in a DSC aluminum pan for testing. Under the condition of 50mL/min and N2, the sample is heated from room temperature to 250°C (or 280°C) at a heating rate of 10°C/min.
- Thermogravimetric analysis (Thermal Gravimetric Analyzer, TGA) method of the present invention
- Test method Take a sample (2 ⁇ 5mg) and place it in a TGA platinum pot for testing. Under the condition of 25mL/min and N2, the sample is heated from room temperature to 300°C or a weight loss of 20% at a heating rate of 10°C/min.
- Fig. 1 is an XRPD spectrum of Form A of the compound of formula (I).
- Fig. 2 is a DSC spectrum of Form A of the compound of formula (I).
- Figure 3 is an XRPD spectrum of Form B of the compound of formula (I).
- Figure 4 is an XRPD spectrum of Form C of the compound of formula (II).
- FIG. 5 is an XRPD spectrum of Form D of the compound of formula (III).
- Fig. 7 is an XRPD spectrum of Form F of the compound of formula (IV).
- Fig. 8 is an XRPD spectrum of the crystalline form G of the compound of formula (IV).
- Fig. 9 is an XRPD spectrum of the crystalline form H of the compound of formula (V).
- Fig. 10 is an XRPD spectrum of the crystalline form I of the compound of formula (V).
- Fig. 11 is an XRPD spectrum of the crystalline form J of the compound of formula (V).
- Fig. 12 is an XRPD spectrum of the crystal form K of the compound of formula (VI).
- 0.2 g of free acid was dissolved in acetonitrile (2 mL) and stirred at 50°C for 30 minutes, 110.08 mg of benzyl star was added and stirred at 50°C for 5 hours, and then cooled to 25°C and stirred for 16 hours. A large amount of white solid was precipitated and filtered. The filter cake was washed with acetonitrile (2 mL ⁇ 3), and the filter cake was concentrated to obtain a white solid.
- parameter Compound I-8 Compound of formula (I) Form A P.O. dose (mg/kg) 300 300 C max (nM) 43467 75167 T max (h) 6 9.3 AUC 0-last (nM.h) 613021 1309787 MRT 0-last (h) 10.6 13.3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
参数 | 化合物I-8 | 式(I)化合物晶型A |
P.O.剂量(mg/kg) | 300 | 300 |
C max(nM) | 43467 | 75167 |
T max(h) | 6 | 9.3 |
AUC 0-last(nM.h) | 613021 | 1309787 |
MRT 0-last(h) | 10.6 | 13.3 |
Claims (24)
- 根据权利要求2所述的晶型A,其特征在于,其使用Cu-Kα测量得到的X射线粉末衍射图谱在九个或更多个、十个或更多个,或十一个或更多个选自下组的2θ角处具有特征衍射峰:5.52±0.2°、13.68±0.2°、18.86±0.2°、19.98±0.2°、20.80±0.2°、21.62±0.2°、22.02±0.2°、22.44±0.2°、23.34±0.2°、24.94±0.2°、26.96±0.2°和28.42±0.2°。
- 根据权利要求3所述的晶型A,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图1所示。
- 根据权利要求2-4任意一项所述的晶型A,其差示扫描量热曲线在239.46℃±3℃处具有吸热峰。
- 根据权利要求5所述的晶型A,其差示扫描量热曲线图谱如图2所示。
- 式(I)化合物的晶型B,其特征在于,其使用Cu-Kα测量得到的X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.68±0.2°、12.36±0.2°、19.24±0.2°、19.86±0.2°、20.62±0.2°、21.64±0.2°、22.68±0.2°和24.96±0.2°。
- 根据权利要求7所述的晶型B,其特征在于,其使用Cu-Kα测量得到的X射线粉末衍射图谱在九个或更多个、十个或更多个,或十一个或更多个选自下组的2θ角处具有特征衍射:5.68±0.2°、12.36±0.2°、13.42±0.2°、19.24±0.2°、19.86±0.2°、20.62±0.2°、21.64±0.2°、22.68±0.2°、24.96±0.2°、26.38±0.2°、27.44±0.2°和30.62±0.2°。
- 根据权利要求8所述的晶型B,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图3所示。
- 式(II)化合物的晶型C,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图4所示。
- 式(III)化合物的晶型D,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图5所示。
- 式(III)化合物的晶型E,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图6所示。
- 式(IV)化合物的晶型F,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图7所示。
- 式(IV)化合物的晶型G,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图8所示。
- 式(V)化合物的晶型H,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图9所示。
- 式(V)化合物的晶型I,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图10所示。
- 式(V)化合物的晶型J,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图11所示。
- 式(VI)化合物的晶型K,其使用Cu-Kα测量得到的X射线粉末衍射图谱如图12所示。
- 根据权利要求1-23任意一项所述化合物或晶型在制备治疗乳腺癌药物中的应用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/295,878 US20220017463A1 (en) | 2018-11-28 | 2019-10-17 | Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor |
JP2021530238A JP7416540B2 (ja) | 2018-11-28 | 2019-10-17 | エストロゲン受容体ダウンレギュレーターの塩形態、結晶形及びその製造方法 |
EP19888746.5A EP3889136A4 (en) | 2018-11-28 | 2019-10-17 | SALINE FOME OF AN ESTROGEN RECEPTOR DOWN-REGULATOR |
KR1020217020007A KR20210097742A (ko) | 2018-11-28 | 2019-10-17 | 에스트로겐 수용체 하향 조절제의 염 형태와 결정형, 및 이의 제조방법 |
CN201980078425.5A CN113166056B (zh) | 2018-11-28 | 2019-10-17 | 一种雌激素受体下调剂的盐型、晶型及其制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811434915 | 2018-11-28 | ||
CN201811434915.8 | 2018-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020108154A1 true WO2020108154A1 (zh) | 2020-06-04 |
Family
ID=70852402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/111624 WO2020108154A1 (zh) | 2018-11-28 | 2019-10-17 | 一种雌激素受体下调剂的盐型、晶型及其制备方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220017463A1 (zh) |
EP (1) | EP3889136A4 (zh) |
JP (1) | JP7416540B2 (zh) |
KR (1) | KR20210097742A (zh) |
CN (1) | CN113166056B (zh) |
WO (1) | WO2020108154A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012037411A2 (en) | 2010-09-16 | 2012-03-22 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
CN106488767A (zh) * | 2014-03-13 | 2017-03-08 | 豪夫迈·罗氏有限公司 | 调节雌激素受体突变体的方法和组合物 |
WO2017162206A1 (zh) | 2016-03-25 | 2017-09-28 | 南京明德新药研发股份有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
WO2019057201A1 (zh) * | 2017-09-25 | 2019-03-28 | 罗欣生物科技(上海)有限公司 | 一种雌激素受体抑制剂的晶型及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106660969A (zh) | 2014-08-11 | 2017-05-10 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂的结晶形式 |
WO2016201356A1 (en) | 2015-06-12 | 2016-12-15 | Adhaere Pharmaceuticals, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
ES2901599T3 (es) | 2016-09-30 | 2022-03-23 | Receptos Llc | Sal de dimetilaminoetanol de un modulador del receptor GLP-1 |
-
2019
- 2019-10-17 KR KR1020217020007A patent/KR20210097742A/ko active Search and Examination
- 2019-10-17 CN CN201980078425.5A patent/CN113166056B/zh active Active
- 2019-10-17 JP JP2021530238A patent/JP7416540B2/ja active Active
- 2019-10-17 WO PCT/CN2019/111624 patent/WO2020108154A1/zh unknown
- 2019-10-17 US US17/295,878 patent/US20220017463A1/en active Pending
- 2019-10-17 EP EP19888746.5A patent/EP3889136A4/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012037411A2 (en) | 2010-09-16 | 2012-03-22 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
CN103189361A (zh) * | 2010-09-16 | 2013-07-03 | 亚拉冈制药公司 | 雌激素受体调节剂及其用途 |
CN106488767A (zh) * | 2014-03-13 | 2017-03-08 | 豪夫迈·罗氏有限公司 | 调节雌激素受体突变体的方法和组合物 |
WO2017162206A1 (zh) | 2016-03-25 | 2017-09-28 | 南京明德新药研发股份有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
WO2019057201A1 (zh) * | 2017-09-25 | 2019-03-28 | 罗欣生物科技(上海)有限公司 | 一种雌激素受体抑制剂的晶型及其制备方法 |
Non-Patent Citations (2)
Title |
---|
J.MEDCHEM., vol. 58, no. 12, 2015, pages 4888 - 4904 |
See also references of EP3889136A4 |
Also Published As
Publication number | Publication date |
---|---|
CN113166056A (zh) | 2021-07-23 |
KR20210097742A (ko) | 2021-08-09 |
JP7416540B2 (ja) | 2024-01-17 |
EP3889136A4 (en) | 2022-08-24 |
JP2022510918A (ja) | 2022-01-28 |
EP3889136A1 (en) | 2021-10-06 |
CN113166056B (zh) | 2024-07-05 |
US20220017463A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3115830C (en) | Compounds for inhibition of .alpha.4.beta.7 integrin | |
AU2014265279B2 (en) | Bipyrazole derivatives as JAK inhibitors | |
JP2021098757A (ja) | Jakキナーゼ阻害剤としてのナフチリジン化合物 | |
BR112021005606A2 (pt) | processo de produção de um composto para inibir a atividade de shp2 | |
WO2017118277A1 (zh) | 一种btk激酶抑制剂的结晶形式及其制备方法 | |
EP3983384B1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
CA3101086A1 (en) | Substituted alkoxypyridinyl indolsulfonamides | |
CA3100795A1 (en) | Pyridinyl and pyrazinyl-(aza)indolsulfonamides | |
CN111253394A (zh) | 选择性cdk4/6抑制剂的固态形式 | |
PT689536E (pt) | Derivados de naftaleno | |
WO2013134298A1 (en) | Raf inhibitor compounds | |
WO2022037647A1 (zh) | 一种选择性Nav抑制剂的结晶形式及其制备方法 | |
MX2014014622A (es) | Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y metodo de preparacion y aplicacion el mismo. | |
BR112019021447A2 (pt) | sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica | |
WO2018210246A1 (zh) | 一种三嗪化合物及其药学上可接受的盐 | |
CA2999332A1 (en) | Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease | |
CA2960101C (en) | Substituted carboline derivative and compositions thereof useful as camkii inhibitors | |
WO2022017494A1 (zh) | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 | |
WO2020108154A1 (zh) | 一种雌激素受体下调剂的盐型、晶型及其制备方法 | |
WO2015113521A1 (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
JPH0253795A (ja) | 新規なエステル | |
KR20200081359A (ko) | 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태 | |
WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
AU2020324561A1 (en) | Quinoline derivatives as protein kinase inhibitors | |
US11034653B2 (en) | Crystal form of estrogen receptor inhibitor and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19888746 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021530238 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217020007 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019888746 Country of ref document: EP Effective date: 20210628 |